Skip to main content
. 2020 May 21;6(7):1–8. doi: 10.1001/jamaoncol.2020.1024

Figure 2. Overall Survival (OS) and Progression-Free Survival (PFS) in All Patients.

Figure 2.

A, The number of events; median OS; OS rates at 6, 12, and 18 months; and the Kaplan-Meier curve for OS in all patients treated with nivolumab or bevacizumab. B, The number of events; median PFS; PFS rates at 6, 12, and 18 months; and the Kaplan-Meier curve for PFS per investigator assessment in patients treated with nivolumab or bevacizumab. Symbols indicate censored observations. Hazard ratios (HRs) and CIs were estimated using a Cox proportional hazards model.